

DRUGS AND DIAGNOSTICS FOR HEMATOLOGICAL DISORDERS: GLOBAL MARKETS



PHM116B
September 2016

Usha Nagavarapu
Project Analyst

ISBN: 1-62296-350-4



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
INTENDED AUDIENCE	2
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
ABOUT BCC RESEARCH	4
CONDITIONS OF PURCHASE	4
ADDITIONAL COPIES	5
CUSTOM ANALYSES	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS, BY SEGMENT, THROUGH 2020 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS, BY SEGMENT, 2012-2020 (\$ MILLIONS)</i>	9
CHAPTER 3 HEMATALOGICAL DISORDERS	11
<i>TABLE 1 KEY BLOOD DISORDERS</i>	11
<i>TABLE 2 MALIGNANT BLOOD DISORDERS</i>	11
<i>TABLE 3 NONMALIGNANT BLOOD DISORDERS</i>	12
BLOOD	13
<i>TABLE 4 TYPE OF BLOOD CELLS AND FUNCTIONS</i>	13
<i>TABLE 5 COMPONENTS OF BLOOD</i>	14
BLOOD DISORDERS/DISEASES	14
ANEMIA	14
Types of Anemia	14
<i>TABLE 6 THREE MAJOR TYPES OF ANEMIA</i>	15
<i>TABLE 7 CAUSES OF ANEMIA</i>	15
Symptoms	16
<i>TABLE 8 SYMPTOMS OF ANEMIA</i>	16
<i>TABLE 9 ANEMIA: TYPES, CAUSES AND TREATMENT</i>	17
MEGALOBLASTIC ANEMIAS	18
Cobalamin Deficiency	18
<i>TABLE 10 DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY BY CLASS</i>	19
Folate Deficiency	19
<i>TABLE 11 DRUGS THAT CAN CAUSE FOLATE DEFICIENCY</i>	20
Diagnostic Tests	20
Schilling Test	20
Serum Ferritin and Iron Studies	21
Other Tests	21

TOPIC	PAGE NO.
Treatment	21
HEMOGLOBIN DISORDERS	22
Categories	22
Thalassemia	22
Sickle Cell Anemia	22
<i>TABLE 12 SICKLE CELL ANEMIA: KEY FACTS</i>	23
Causes	23
World Health Organization's Resolutions	24
HEMOLYTIC ANEMIA	24
<i>TABLE 13 LAB TESTS FOR ANEMIA</i>	24
Treatment	25
Anemia Medications	25
PRIMARY THROMBOCYTHEMIA	26
Hemostasis: Steps of Mechanism	26
<i>TABLE 14 HEMOSTASIS: THREE MAJOR STEPS</i>	27
Types of Hemostasis	27
Hemostasis in Emergency Medicine	27
Artificial Hemostasis	28
<i>TABLE 15 DRUGS THAT AFFECT THE ACTIVITY OF PLATELETS</i>	29
<i>TABLE 16 ANTICOAGULANTS THAT ACT ON THROMBIN</i>	29
BLEEDING DISORDERS	30
<i>TABLE 17 BLEEDING DISORDERS</i>	30
<i>TABLE 18 SYMPTOMS OF BLEEDING DISORDERS</i>	31
<i>TABLE 19 SIGNS AND TESTS FOR BLEEDING DISORDERS</i>	31
Hemophilia	31
<i>TABLE 20 KEY CHARACTERISTICS OF HEMOPHILIA</i>	32
Classification	32
Historical Background	33
The Clotting Cascade	33
Hemorrhage	34
Natural Inhibitors	34
Acquired Hemophilia	35
Hemophilia Types	35
Symptoms and Complications	35
Diagnosis	36
Hemophilia and Bleeding	36
Genetic Testing	37
Treatment	37
<i>TABLE 21 FVIII INHIBITORS</i>	40
<i>TABLE 22 MEDICATIONS FOR TREATING HEMOPHILIA</i>	41
Factor VIII Products	41
<i>TABLE 23 FACTOR VIII PRODUCTS</i>	42
Antifibrinolytics	42
<i>TABLE 24 ANTIFIBRINOLYTICS BY DRUG</i>	42
Antihemophilic Agents	42
<i>TABLE 25 ANTIHEMOPHILIC AGENTS BY CLASS</i>	43
Coagulation Factor VIIa, Recombinants	43

TOPIC	PAGE NO.
Factor VIIa, Recombinant (NovoSeven)	43
Monoclonal Antibodies	43
Rituximab (Rituxan)	44
von Willebrand Disease	44
Symptoms and Diagnosis	44
Treatment	44
THROMBOPHILIA	45
Diagnosis and Treatment	45
THROMBOSIS	46
<i>TABLE 26 FORMATION OF THROMBUS</i>	47
Superficial Thrombophlebitis	47
DEEP VENOUS THROMBOSIS	47
Tests	47
Treatment	48
Surgery	49
HEREDITARY HEMORRHAGIC TELANGIECTASIA	49
ERYTHROCYTOSIS	50
Absolute Polycythemia	50
Types	50
Primary Polycythemia	50
Secondary Polycythemia	50
Chuvash Polycythemia	51
Relative Polycythemia	51
WHITE BLOOD CELL DISORDERS	52
Treatment	52
NEUTROPENIA	53
Causes	53
<i>TABLE 27 CAUSES OF NEUTROPENIA</i>	53
Symptoms and Diagnosis	54
Treatment	54
NEUTROPHILIA	55
BLOOD DISORDERS AFFECTING PLATELETS	55
<i>TABLE 28 WHITE BLOOD CELL DISORDERS</i>	55
Thrombocytopenia	56
Treatment	56
Lymphocytopenia	56
Treatment	57
Lymphocytic Leukocytosis	57
Monocytosis	57
Thrombocythemia and Thrombocytosis	58
Types	58
Primary Thrombocythemia	58
Secondary Thrombocytosis	58
<i>TABLE 29 CAUSES OF SECONDARY THROMBOCYTOSIS</i>	59
Symptoms	59
<i>TABLE 30 DIAGNOSTIC TESTS FOR THROMBOCYTHEMIA</i>	60
Treatment	60

TOPIC	PAGE NO.
<i>TABLE 31 MEDICINES FOR THROMBOCYTHEMIA</i>	61
Thrombocytopenia	61
Causes	61
<i>TABLE 32 CAUSES OF THROMBOCYTOPENIA</i>	62
RARE CONDITIONS THAT CAUSE BLOOD CLOTS	63
Signs and Symptoms	63
<i>TABLE 33 SIGNS OF EXTERNAL BLEEDING</i>	63
Tests	63
Treatment	64
SEVERE THROMBOCYTOPENIA	64
EOSINOPHILS AND DISORDERS	64
<i>TABLE 34 COMMON DRUGS TO TREAT EOSINOPHILIA</i>	65
BASOPHILIC DISORDERS	65
PLASMA CELL DISORDERS	65
CHAPTER 4 HEMATOLOGICAL CANCERS	68
<i>TABLE 35 HEMATOLOGICAL CANCERS (BLOOD CANCERS)</i>	68
CLASSIC CLASSIFICATION	69
<i>TABLE 36 RELATIVE OCCURRENCE OF HEMATOLOGICAL MALIGNANCIES IN THE U.S., 2016 (NUMBER/%)</i>	69
<i>TABLE 37 TYPES OF HEMATOLOGICAL CANCERS</i>	70
ACUTE MYELOID LEUKEMIA	71
CHRONIC MYELOID LEUKEMIA	71
ACUTE LYMPHOCYTIC LEUKEMIA	72
CHRONIC LYMPHOCYTIC LEUKEMIA	72
HODGKIN LYMPHOMA	72
NON-HODGKIN LYMPHOMA	73
Treatment and Side Effects	73
MULTIPLE MYELOMA	73
MYELODYSPLASTIC SYNDROME	74
Diagnosis	74
<i>TABLE 38 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2014-2016</i>	74
<i>TABLE 39 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2012</i>	77
<i>TABLE 40 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2011</i>	78
<i>TABLE 41 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 1996-2010</i>	79
CHAPTER 5 LEUKEMIA	83
LYMPHOCYTIC LEUKEMIAS	84
MYELOGENOUS LEUKEMIAS	84
<i>TABLE 42 TYPES OF LEUKEMIA</i>	84
<i>TABLE 43 TYPES OF LEUKEMIA AND KEY FEATURES</i>	85
SYMPTOMS	86
CAUSES	87
DIAGNOSIS	88

TOPIC	PAGE NO.
TESTS	88
<i>TABLE 44 DIAGNOSTIC EXAMS FOR LEUKEMIA</i>	89
Complete Blood Count	89
White Cell Differential	89
Blood Smear	89
<i>TABLE 45 ADDITIONAL TESTS</i>	89
Fluorescence In Situ Hybridization (FISH)	90
Flow Cytometry	90
Immunophenotyping	90
Karyotype Test	91
Polymerase Chain Reaction	91
Bone Marrow Aspiration/Biopsy	91
Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis	91
Immunophenotyping or Phenotyping by Flow Cytometry	91
Cytogenetics and Fluorescent In Situ Hybridization	92
Polymerase Chain Reaction (PCR)	92
<i>TABLE 46 PCR TESTS</i>	92
Non-Laboratory Tests	92
<i>TABLE 47 NON-LABORATORY TESTS</i>	92
TREATMENT	93
<i>TABLE 48 COMMON TREATMENTS USED TO FIGHT LEUKEMIA</i>	93
<i>TABLE 49 NEWER CLASSES OF DRUGS</i>	94
Drug Therapies for Blood Cancers	94
<i>TABLE 50 ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT</i>	96
<i>TABLE 51 DRUGS APPROVED FOR ACUTE LYMPHOBLASTIC LEUKEMIA</i>	97
<i>TABLE 52 DRUGS APPROVED FOR CHRONIC LYMPHOCYTIC LEUKEMIA</i>	98
<i>TABLE 53 DRUGS APPROVED FOR ACUTE MYELOID LEUKEMIA</i>	99
<i>TABLE 54 DRUGS APPROVED FOR CHRONIC MYELOGENOUS LEUKEMIA</i>	100
Hairy Cell Leukemia: Treatment	100
T-CELL PROLYMPHOCYTIC LEUKEMIA	101
<i>TABLE 55 T-CELL PROLYMPHOCYTIC LEUKEMIA: TREATMENT PLAN</i>	101
JUVENILE MYELOMONOCYTIC LEUKEMIA	101
STAGES OF LEUKEMIA	102
<i>TABLE 56 FACTORS AFFECTING LEUKEMIA STAGING AND PROGNOSIS</i>	102
TREATMENTS AND DRUGS	102
Stem Cell Transplantation	102
Allogeneic Stem Cell Transplant	102
Autologous Stem Cell Transplant	103
Chemotherapy	103
Types of Chemotherapy for Leukemia	103
Chemotherapy for Acute Leukemias	103
Chemotherapy for Chronic Leukemias	104
<i>TABLE 57 CHEMOTHERAPY DRUGS FOR CML</i>	104
<i>TABLE 58 CHEMOTHERAPY DRUGS FOR CLL</i>	104
Intrathecal Chemotherapy	104
Targeted Drug Therapy for Leukemia	104
<i>TABLE 59 TARGETED THERAPY DRUGS</i>	105

TOPIC	PAGE NO.
Monoclonal Antibody Therapy	105
Radioimmunotherapy	105
<i>TABLE 60 ADVANTAGES OF RADIOIMMUNOTHERAPY</i>	106
Radiation Therapy	106
<i>TABLE 61 COMMON RADIATION TREATMENTS: LEUKEMIA</i>	106
External Beam Radiation Therapy	107
Total Body Irradiation	107
Total Marrow Irradiation	107
Nutrition Therapy after a Stem Cell Transplant	107
Managing Side Effects with Naturopathic Therapies	108
Pain Management for Leukemia	108
<i>TABLE 62 PAIN MEDICATIONS</i>	108
<i>TABLE 63 EMERGING THERAPIES FOR LEUKEMIA</i>	108
CONCLUSIONS	109
CHAPTER 6 LYMPHOMA	111
OVERVIEW	111
LYMPHOMA CAUSES	112
<i>TABLE 64 CAUSES OF LYMPHOMA</i>	113
CLASSIFICATION	113
<i>TABLE 65 LYMPHOMA TYPES</i>	114
STAGING	115
<i>TABLE 66 STAGING FOR HL AND NHL TUMORS</i>	116
NON-HODGKIN LYMPHOMA	116
<i>TABLE 67 MATURE B-CELL NEOPLASMS</i>	117
<i>TABLE 68 MATURE T-CELL AND NATURAL KILLER CELL NEOPLASMS</i>	117
<i>TABLE 69 HODGKIN LYMPHOMA</i>	118
<i>TABLE 70 IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS</i>	118
SIGNS AND SYMPTOMS	118
<i>TABLE 71 SYMPTOMS OF NON-HODGKIN LYMPHOMA</i>	119
<i>TABLE 72 FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS: NON HODGKIN LYMPHOMA, 2006-2012 (%)</i>	119
DIAGNOSIS AND TESTS	120
Biopsy	120
Imaging Studies	120
<i>TABLE 73 IMAGING TESTS FOR LYMPHOMA</i>	120
Bone Marrow Examination	121
Other Tests	121
Lumbar Puncture	121
Organ Function Tests	121
PROGNOSTIC FACTORS	121
<i>TABLE 74 THE INTERNATIONAL PROGNOSTIC INDEX FOR HL</i>	121
<i>TABLE 75 THE INTERNATIONAL PROGNOSTIC INDEX FOR NHL</i>	122
LYMPHOMA TREATMENT	122
RADIATION AND CHEMOTHERAPY	123
RADIATION THERAPY	123
CHEMOTHERAPY	123
BIOLOGICAL THERAPY	124

TOPIC	PAGE NO.
<i>TABLE 76 PROMISING THERAPIES FOR TREATING LYMPHOMA</i>	124
COMPLEMENTARY/ALTERNATIVE THERAPIES	124
CHAPTER 7 MULTIPLE MYELOMA	127
OVERVIEW	127
CAUSE	128
SYMPTOMS	128
COMPLICATIONS OF MYELOMA	129
Cryoglobulinemia	129
Amyloidosis	129
TYPES OF MYELOMA	129
INCIDENCE	130
DIAGNOSIS	130
TESTS	131
Prognostic Indicators	132
<i>TABLE 77 PROGNOSTIC INDICATORS FOR MYELOMA</i>	132
Bone Marrow Examination	132
<i>TABLE 78 OTHER BONE MARROW TESTS</i>	132
STAGING	133
Monoclonal Gammopathy of Undetermined Significance	133
Smoldering Multiple Myeloma	134
Indolent Multiple Myeloma	134
Symptomatic Multiple Myeloma	134
<i>TABLE 79 MYELOMA: STAGING CRITERIA</i>	134
TREATMENT AND PROGNOSIS	135
<i>TABLE 80 MYELOMA'S RESPONSE TO TREATMENT</i>	135
Myeloma Therapy	136
Chemotherapy	136
Radiation Therapy	136
Stem Cell Transplantation	137
Supportive Care	138
<i>TABLE 81 SUPPORTIVE CARE FOR MYELOMA</i>	138
OTHER DRUG THERAPIES	138
NEW DRUG THERAPIES	139
<i>TABLE 82 DRUGS FOR MULTIPLE MYELOMA</i>	140
<i>TABLE 83 NEW AND EMERGING THERAPIES FOR MYELOMA</i>	141
CONCLUSIONS	144
CHAPTER 8 MYELOYDYSPLASTIC SYNDROMES	147
<i>TABLE 84 CHARACTERISTICS OF MDS</i>	147
<i>TABLE 85 CAUSES OF MDS</i>	148
<i>TABLE 86 MDS OR AML: THREE CATEGORIES</i>	148
CLASSES OF MDS	149
<i>TABLE 87 MYELOYDYSPLASTIC SYNDROMES: KEY FACTS</i>	149
<i>TABLE 88 FAB CLASSIFICATION OF MDS</i>	150
<i>TABLE 89 THE 2008 WHO CLASSIFICATION OF MDS</i>	151
INTERNATIONAL PROGNOSTIC SCORING SYSTEM	151

TOPIC	PAGE NO.
<i>TABLE 90 INTERNATIONAL PROGNOSTIC SCORING SYSTEM RISK GROUPS AND PROGNOS (YEARS)</i>	152
DIAGNOSIS AND TESTS	152
<i>TABLE 91 CHANGES IN CELLS DUE TO MDS</i>	153
PROGNOSIS AND TREATMENT OPTIONS	154
CHEMOTHERAPY	154
SUPPORTIVE CARE	154
DRUG PROFILES	156
EPOETIN ALFA (PROCRIT, EPOGEN)	156
DARBEPOETIN (ARANESP)	157
SARGRAMOSTIM (LEUKINE)	157
FILGRASTIM (NEUPOGEN)	157
DECITABINE (DACOGEN)	157
LENALIDOMIDE (REVLIMID)	157
VIDAZA (AZACITIDINE)	158
PREVIOUSLY TREATED MYELOYDYSPLASTIC SYNDROMES	158
CONCLUSIONS	158
CHAPTER 9 MYELOPROLIFERATIVE DISORDERS	162
TYPES OF CHRONIC MYELOPROLIFERATIVE DISORDERS	162
<i>TABLE 92 CHRONIC MYELOPROLIFERATIVE DISORDERS</i>	163
CLASSIFICATION: WHO	167
<i>TABLE 93 CLASSIFICATION OF MYELOID NEOPLASMS ACCORDING TO THE 2008 WHO CLASSIFICATION SCHEME</i>	167
<i>TABLE 94 MYELOPROLIFERATIVE NEOPLASMS: KEY FACTS</i>	169
STAGES OF CHRONIC MYELOPROLIFERATIVE DISORDERS	169
DIAGNOSIS	169
TESTS	169
<i>TABLE 95 DIAGNOSTIC TESTS</i>	170
TREATMENT	170
OTHER DRUG THERAPY	170
POLYCYTHEMIA VERA	170
OVERVIEW	171
<i>TABLE 96 SYMPTOMS OF POLYCYTHEMIA VERA</i>	171
CAUSES	172
RISK FACTORS	172
<i>TABLE 97 BLOOD TESTS FOR POLYCYTHEMIA VERA</i>	172
TREATMENT OF POLYCYTHEMIA VERA	172
Drugs for Treating Polycythemia Vera	173
<i>TABLE 98 TREATMENT FOR POLYCYTHEMIA VERA</i>	173
PROGNOSIS	173
COMPLICATIONS	174
Blood Clots	174
Enlarged Spleen (Splenomegaly)	174
Problems Due to High Levels of Red Blood Cells	174
OTHER BLOOD DISORDERS	174
CHRONIC IDIOPATHIC MYELOFIBROSIS	174
CAUSES	174

TOPIC	PAGE NO.
<i>TABLE 99 CAUSATIVE FACTORS FOR MYELOFIBROSIS</i>	175
<i>TABLE 100 POTENTIAL COMPLICATIONS FROM MYELOFIBROSIS</i>	175
PATHOGENESIS	176
DIAGNOSIS	176
<i>TABLE 101 WHO DIAGNOSTIC CRITERIA FOR PMF</i>	177
PROGNOSIS	177
<i>TABLE 102 RISK FACTORS</i>	178
SYMPTOMS	178
<i>TABLE 103 IDIOPATHIC MYELOFIBROSIS AND SYMPTOMS</i>	178
<i>TABLE 104 PROGNOSIS FACTORS</i>	179
TREATMENTS FOR MYELOFIBROSIS	179
<i>TABLE 105 TREATMENT OF CHRONIC IDIOPATHIC MYELOFIBROSIS</i>	181
Experimental Drug Therapy	181
Pomalidomide	182
<i>TABLE 106 SOMATIC MUTATIONS</i>	183
ESSENTIAL THROMBOCYTHEMIA	183
<i>TABLE 107 CAUSES OF THROMBOCYTOSIS</i>	184
SYMPTOMS	184
<i>TABLE 108 SYMPTOMS OF ESSENTIAL THROMBOCYTOSIS</i>	185
PATHOPHYSIOLOGY	185
DIAGNOSIS	185
<i>TABLE 109 ESSENTIAL THROMBOCYTHEMIA: DIAGNOSTIC CRITERIA</i>	186
TREATMENT	186
PROGNOSIS	186
CAUSES, INCIDENCE AND RISK FACTORS	187
GENES: ESSENTIAL THROMBOCYTHEMIA	187
TREATMENT OF ESSENTIAL THROMBOCYTHEMIA	187
Diagnosis	188
<i>TABLE 110 TREATMENT OF ET</i>	189
ANTI-PLATELET TREATMENT	189
ADP RECEPTOR ANTAGONISTS	190
PLATELET-LOWERING TREATMENT	190
Anagrelide	190
Interferon-a (IFN-a)	190
ALTERNATIVE CYTOREDUCTIVE THERAPY	191
Pipobroman (PI)	191
Busulfan (BU)	191
Prognosis	191
Implication of the Description of JAK2 V617F Mutation on the Management of ET	192
CHRONIC NEUTROPHILIC LEUKEMIA	192
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA	192
<i>TABLE 111 TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA</i>	192
CHRONIC EOSINOPHILIC LEUKEMIA	192
<i>TABLE 112 SYMPTOMS OF CHRONIC EOSINOPHILIC LEUKEMIA</i>	193
TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA	193
<i>TABLE 113 TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA</i>	193
PIPELINE DRUGS	193

TOPIC	PAGE NO.
Incyte	193
Jakavi in Europe	195
SUMMARY	195
TABLE 114 CURRENT DRUGS	196
CHAPTER 10 EPIDEMIOLOGY OF HEMATOLOGICAL CANCERS	198
TABLE 115 CANCER KEY FACTS	199
TABLE 116 INCREASE IN CANCER BURDEN: FACTORS	200
INDIA	201
KENYA	201
WORLDWIDE INCIDENCE OF BLOOD CANCERS	202
TABLE 117 GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO./%)	203
TABLE 118 GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO.)	203
TABLE 119 GLOBAL INCIDENCE OF BLOOD CANCERS IN MEN, 2012 (NO./%)	204
TABLE 120 GLOBAL INCIDENCE OF BLOOD CANCERS IN WOMEN, 2012 (NO./%)	204
TABLE 121 TOP 10 COUNTRIES' CANCER INCIDENCE RATES (PER 100,000 POPULATION)	205
BLOOD CANCER INCIDENCE IN THE UNITED STATES	205
TABLE 122 ESTIMATED INCIDENCE OF BLOOD CANCERS IN THE U.S., 2011 VS. 2016 (PER 100,000 POPULATION)	206
FIGURE 1 ESTIMATED INCIDENCE OF BLOOD CANCERS, IN THE U.S., 2011 VS. 2016 (PER 100,000 POPULATION)	207
TABLE 123 ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2016 (NO.)	208
FIGURE 2 ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2016 (NO.)	208
TABLE 124 ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)	209
FIGURE 3 ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)	209
DEATHS FROM BLOOD CANCERS	210
LEUKEMIA	210
NUCLEAR REACTORS AND BLOOD CANCERS	210
SIGNS AND SYMPTOMS	211
LEUKEMIA IN CHILDREN AND ADOLESCENTS	212
GLOBAL INCIDENCE	212
TABLE 125 GLOBAL INCIDENCE OF LEUKEMIA, 2012 (NUMBER/%)	213
LEUKEMIA IN THE UNITED STATES	213
TABLE 126 U.S. LEUKEMIA INCIDENCE STATISTICS, 2012	214
TABLE 127 ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S., 2010-2016 (NO.)	214
FIGURE 4 ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S., 2010-2016 (NO.)	215
TABLE 128 ESTIMATED NEW CASES OF LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2016	215
TABLE 129 ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008 (NO.)	216
FIGURE 5 ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008 (NO.)	216
Leukemia in Children and Adolescents	216

TOPIC	PAGE NO.
<i>TABLE 130 PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.)</i>	217
<i>FIGURE 6 PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.)</i>	218
Adolescents and Young Adults	218
Adults	219
<i>TABLE 131 TYPES OF LEUKEMIA IN ADULTS IN THE U.S. AND AGE GROUP</i>	219
<i>TABLE 132 ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE, 2012 (NO.)</i>	219
<i>FIGURE 7 ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE, 2012 (NO.)</i>	220
<i>TABLE 133 AGE-ADJUSTED INCIDENCE RATES OF LEUKEMIA IN THE U.S. BY RACE, SEER 18, 2009-2013 (PER 100,000 POPULATION)</i>	221
Survival	221
<i>TABLE 134 FIVE-YEAR RELATIVE SURVIVAL RATES IN THE U.S. FOR LEUKEMIA, 2005-2011 (%)</i>	221
<i>TABLE 135 ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO.)</i>	222
<i>FIGURE 8 ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO.)</i>	222
LEUKEMIA INCIDENCE IN THE UNITED KINGDOM	223
<i>TABLE 136 NEW CASES OF LEUKEMIA IN THE U.K., 2013 (NO.)</i>	223
Cause	226
WORLDWIDE MORTALITY RATES: LEUKEMIA	226
<i>TABLE 137 GLOBAL ESTIMATES OF LEUKEMIA DEATHS/MORTALITY RATES, 2012</i>	227
LYMPHOMA	228
SIGNS AND SYMPTOMS	229
POSSIBLE CAUSES	229
TREATMENT	230
WORLDWIDE INCIDENCE OF NHL	230
<i>TABLE 138 GLOBAL ESTIMATED INCIDENCE RATES OF NON-HODGKIN LYMPHOMA FOR ALL AGES AND BOTH SEXES, 2012</i>	230
<i>TABLE 139 GLOBAL ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES BY ALL AGES AND BOTH SEXES, 2012</i>	231
GLOBAL INCIDENCE OF HODGKIN'S LYMPHOMA	232
<i>TABLE 140 GLOBAL ESTIMATED INCIDENCE OF HODGKIN LYMPHOMA FOR ALL AGES AND BOTH SEXES, 2012</i>	233
CANADA: LYMPHOMA	233
EUROPEAN UNION	234
Non-Hodgkin's Lymphoma	234
<i>TABLE 141 ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)</i>	234
<i>FIGURE 9 ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)</i>	235
<i>TABLE 142 ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)</i>	236
<i>FIGURE 10 ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000)</i>	237
Hodgkin Lymphoma in EU: 2012	237
<i>TABLE 143 ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES IN EU-27 COUNTRIES, 2012 (ESTIMATED RATES PER 100,000 POPULATION)</i>	238

TOPIC	PAGE NO.
<i>FIGURE 11 ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES IN EU-27 COUNTRIES, 2012 (ESTIMATED RATES PER 100,000 POPULATION)</i>	239
LYMPHOMA IN THE UNITED STATES	240
New Cases	240
<i>TABLE 144 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)</i>	240
<i>FIGURE 12 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)</i>	241
<i>TABLE 145 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2012 (NO.)</i>	242
<i>FIGURE 13 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2012 (NO.)</i>	242
<i>TABLE 146 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE, 2011-2016 (NO.)</i>	243
<i>FIGURE 14 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE, 2011-2016 (NO.)</i>	243
<i>TABLE 147 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2012 (NO.)</i>	244
<i>FIGURE 15 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2012 (NO.)</i>	244
<i>TABLE 148 ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2011 (NO.)</i>	245
<i>FIGURE 16 ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2011 (NO.)</i>	245
<i>TABLE 149 U.S. AGE-SPECIFIC NHL INCIDENCE RATES BY GENDER (ESTIMATED RATES PER 100,000 POPULATION)</i>	245
<i>TABLE 150 U.S. LYMPHOMA INCIDENCE RATES BY RACE, 2005-2009 (PER 100,000 POPULATION)</i>	246
<i>TABLE 151 U.S. LYMPHOMA MORTALITY RATES BY RACE, 2005-2009 (PER 100,000 POPULATION)</i>	246
Race and Ethnicity	247
Children	247
Adolescents and Young Adults	247
Adults	248
Survival	248
<i>TABLE 152 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACES, BOTH SEXES BY STAGE AT DIAGNOSIS, 2002-2008 (%)</i>	249
LYMPHOMA IN THE UNITED KINGDOM	249
<i>TABLE 153 NEW CASES OF NON-HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.)</i>	250
<i>TABLE 154 NON-HODGKIN LYMPHOMA DEATHS IN THE U.K. BY SEX, 2012 (NO.)</i>	253
Hodgkin Lymphoma in the United Kingdom	253
<i>TABLE 155 ESTIMATED NUMBER OF NEW CASES OF HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.)</i>	254
<i>TABLE 156 ESTIMATED NUMBER OF DEATHS FROM HODGKIN'S LYMPHOMA IN THE U.K., 2012 (NO.)</i>	255
<i>FIGURE 17 ESTIMATED NUMBER OF DEATHS FROM HODGKIN'S LYMPHOMA IN THE U.K., 2012 (NO.)</i>	255
MYELOMA	256
SYMPTOMS	256
MYELOMA INCIDENCE WORLDWIDE	256

TOPIC	PAGE NO.
TABLE 157 ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER 100,000 POPULATION)	257
FIGURE 18 ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER 100,000 POPULATION)	258
TABLE 158 ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, 2008 (PER 100,000 POPULATION)	259
FIGURE 19 ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, 2008 (PER 100,000 POPULATION)	260
MYELOMA IN EUROPEAN UNION COUNTRIES	261
TABLE 159 ESTIMATED INCIDENCE OF MYELOMA IN EU-27 COUNTRIES, 2012 (NO.)	261
TABLE 160 DEATHS FROM MYELOMA IN EU-27 COUNTRIES, 2012 (NO.)	263
MYELOMA IN THE UNITED STATES	264
TABLE 161 ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016 (NO.)	264
FIGURE 20 ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016 (NO.)	265
TABLE 162 ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S., 2011-2016 (NO.)	265
FIGURE 21 ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S., 2011-2016 (NO.)	265
TABLE 163 AGE-ADJUSTED INCIDENCE RATES OF MYELOMA IN THE U.S. BY RACE, SEER 18 2009-2013 (PER 100,000 POPULATION)	267
TABLE 164 AGE-ADJUSTED DEATH RATES FROM MYELOMA IN THE U.S. BY RACE, SEER 18 2009-2013 (PER 100,000 POPULATION)	268
Survival	268
TABLE 165 DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL FOR ALL AGES AND BOTH SEXES IN THE U.S. BY STAGE AT DIAGNOSIS, 2002-2008 (%)	268
MYELOMA IN THE UNITED KINGDOM	269
TABLE 166 NEW CASES OF MYELOMA IN THE U.K., 2013 (NO.)	270
TABLE 167 MYELOMA DEATHS IN THE U.K., 2012 (NO.)	271
CONCLUSIONS	271
MYELODYSPLASTIC SYNDROMES	271
SIGNS AND SYMPTOMS	272
TABLE 168 ESTIMATED NEW CASES OF MDS IN THE U.S., 2012 (NO.)	273
RACE AND ETHNICITY	274
BLOOD DISEASES AND INCIDENCE	274
ANEMIA	275
SICKLE CELL ANEMIA	275
THALASSEMIA	276
BLEEDING DISORDERS	277
HEMOPHILIA	277
Worldwide Incidence of Hemophilia	278
Mortality/Morbidity	278
Hemophilia in the United States	279
CLOTTING DISORDERS	279
CHAPTER 11 HEMATOLOGY INSTRUMENTS AND REAGENTS: A GLOBAL MARKET PERSPECTIVE	282
HEMATOLOGICAL MALIGNANCIES	282
MARKET DYNAMICS: HEMATOLOGY INSTRUMENTS AND REAGENTS	282

TOPIC	PAGE NO.
<i>TABLE 169 KEY FACTORS DRIVING THE GROWTH OF THE HEMATOLOGICAL DISORDERS MARKET</i>	283
<i>TABLE 170 GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	284
<i>FIGURE 22 GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, 2012-2020 (\$ MILLIONS)</i>	284
GLOBAL MARKET	285
Market Drivers	285
<i>TABLE 171 KEY HEMATOLOGY PRODUCTS</i>	286
Key Players in Hematology Instruments	286
<i>TABLE 172 GLOBAL MAJOR COMPANIES IN THE HEMATOLOGY MARKET</i>	287
Key Company Profiles	287
Roche	287
Sysmex	288
Flow Cytometers	288
<i>TABLE 173 KEY PLAYERS IN FLOW CYTOMETRY</i>	289
<i>TABLE 174 GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	290
<i>FIGURE 23 GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET, 2012-2020 (\$ MILLIONS)</i>	290
<i>TABLE 175 MAJOR FLOW CYTOMETRY APPLICATIONS</i>	291
Coagulation Analyzers	291
<i>TABLE 176 CELL ANALYZERS</i>	292
Future Outlook	293
HEMATOLOGY TEST PRODUCTS AND MARKET	294
<i>TABLE 177 HEMATOLOGY TESTS</i>	294
COMPLETE BLOOD COUNT (CBC)	295
<i>TABLE 178 COMPLETE BLOOD COUNT: COMPONENTS MEASURED</i>	295
MAJOR ROUTINE AND SPECIAL HEMATOLOGY TESTS	296
Partial Thromboplastin Time	296
Total Serum Protein	296
Chemistry Panel	296
<i>TABLE 179 TESTS INCLUDED IN A CHEMISTRY SCREEN</i>	297
<i>TABLE 180 CHEMISTRY SCREEN</i>	297
Vitamin B12	297
The Cold Agglutinins Test	298
Prothrombin	298
Reticulocyte	298
Urine Cytology	298
<i>TABLE 181 URINE TESTS AND APPLICATIONS</i>	299
BLOOD PROTEIN TESTING	299
TUMOR MARKER TESTS	300
IN VITRO DIAGNOSTIC MARKET	300
<i>TABLE 182 GLOBAL IVD PRODUCTS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	301
<i>FIGURE 24 GLOBAL IVD PRODUCTS MARKET, 2012-2020 (\$ MILLIONS)</i>	301
<i>TABLE 183 U.S. IVD MARKET, THROUGH 2020 (\$ MILLIONS)</i>	302
<i>FIGURE 25 U.S. IVD MARKET, 2012-2020 (\$ MILLIONS)</i>	302
Immunoassays	303

TOPIC	PAGE NO.
<i>TABLE 184 GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, THROUGH 2020 (\$ MILLIONS)</i>	303
<i>FIGURE 26 GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, 2012-2020 (\$ MILLIONS)</i>	303
Market Trends	303
<i>TABLE 185 GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, THROUGH 2020 (\$ MILLIONS)</i>	304
<i>FIGURE 27 GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, 2015-2020 (\$ MILLIONS)</i>	304
<i>TABLE 186 KEY PLAYERS IN THE IMMUNOASSAYS MARKET</i>	305
Molecular Diagnostics	305
<i>TABLE 187 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	306
<i>FIGURE 28 GLOBAL MOLECULAR DIAGNOSTICS MARKET, 2015-2020 (\$ MILLIONS)</i>	306
<i>TABLE 188 MAJOR PLAYERS IN MOLECULAR DIAGNOSTICS MARKET</i>	307
POINT-OF-CARE MARKET	307
<i>TABLE 189 GLOBAL POINT-OF-CARE TESTING MARKET, THROUGH 2020 (\$ MILLIONS)</i>	308
<i>FIGURE 29 GLOBAL POINT-OF-CARE TESTING MARKET, 2015-2020 (\$ MILLIONS)</i>	308
<i>TABLE 190 POC TESTING KITS</i>	309
POC Tests	309
<i>TABLE 191 GLOBAL MARKET FOR POC TESTS, THROUGH 2020 (\$ MILLIONS)</i>	309
<i>FIGURE 30 GLOBAL MARKET FOR POC TESTS, 2015-2020 (\$ MILLIONS)</i>	309
POC Immunoassays	310
<i>TABLE 192 GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, THROUGH 2020 (\$ MILLIONS)</i>	311
<i>FIGURE 31 GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, 2015-2020 (\$ MILLIONS)</i>	311
Cardiac Markers	311
<i>TABLE 193 TYPES OF CARDIAC MARKERS</i>	312
POC Market Penetration	312
Future Outlook	312
BLOOD TRANSFUSION DIAGNOSTIC AND BLOOD SCREENING MARKET	313
<i>TABLE 194 KEY MARKET PLAYERS IN THE BLOOD SCREENING MARKET</i>	314
CONCLUSIONS	314
CHAPTER 12 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS	316
THERAPEUTIC DRUG MARKET	316
<i>TABLE 195 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS, BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	316
<i>FIGURE 32 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS, BY TYPE, 2012-2020 (\$ MILLIONS)</i>	316
<i>TABLE 196 GLOBAL MARKET SHARES OF TREATMENTS FOR HEMATOLOGICAL DISORDERS BY TYPE, 2015 AND 2020 (%)</i>	317
KEY MARKET PLAYERS	318
<i>TABLE 197 PATENT EXPIRIES OF MAJOR BLOCKBUSTERS DRUGS</i>	318
<i>TABLE 198 GLOBAL KEY PLAYERS OF HEMATOLOGICAL DISORDERS MARKET BY PRODUCTS AND MARKET SHARE, 2015 (%)</i>	318
<i>TABLE 199 MARKET DRIVERS OF HEMATOLOGICAL DISORDERS</i>	319
<i>TABLE 200 MARKET RESTRAINTS OF HEMATOLOGICAL DISORDERS</i>	319

TOPIC	PAGE NO.
ANEMIA TREATMENT MARKET	319
TABLE 201 GLOBAL ANEMIA TREATMENT MARKET, THROUGH 2020 (\$ MILLIONS)	320
FIGURE 33 GLOBAL ANEMIA TREATMENT MARKET, 2012-2020 (\$ MILLIONS)	320
TABLE 202 TYPES OF ANEMIA	320
Anemia Treatments	321
TABLE 203 COMMON ANEMIA TREATMENTS	321
TABLE 204 ERYTHROPOIETIN STIMULATING AGENTS	322
Aranesp	322
TABLE 205 KEY ANEMIA DRUGS SALES, 2012 AND 2015 (\$ MILLIONS)	323
FIGURE 34 KEY ANEMIA DRUGS SALES, 2012 AND 2015 (\$ MILLIONS)	323
Epogen	324
Procrit	324
Costs	325
NeoRecormon	325
TABLE 206 GLOBAL NEORECORMON MARKET, 2010-2015* (\$ MILLIONS)	325
FIGURE 35 GLOBAL NEORECORMON MARKET, 2010-2015* (\$ MILLIONS)	325
TABLE 207 GLOBAL NEORECORMON MARKET, 2009 (\$ MILLIONS)	326
Biosimilars	327
TABLE 208 BIOSIMILARS OF EPOETIN ALFA AND DARBEPOETIN ALFA	327
Medicare and Anemia Drug Usage	329
Market Trends	329
Drug Profiles	330
Promacta (Eltrombopag)	330
Roxadustat	330
Peginesatide	331
Future Strategies	331
Major Players	334
GlaxoSmithKline and Bayer	334
FibroGen	334
Stanford	335
Ligand	335
Pluristem Therapeutics	335
AMAG Pharma	336
Akebia Therapeutics	336
TABLE 209 AKEBIA THERAPEUTICS: ANEMIA DRUG IN DEVELOPMENT-AKB-6548	337
THROMBOSIS TREATMENT MARKET	337
TABLE 210 GLOBAL ANTITHROMBOTIC DRUG MARKET, BY TYPE, THROUGH 2020 (\$ MILLIONS)	338
FIGURE 36 GLOBAL ANTITHROMBOTIC DRUG MARKET, BY TYPE, 2012-2020 (\$ MILLIONS)	338
TABLE 211 LEADING DRUGS IN THE ANTITHROMBOTIC AGENTS MARKET	339
Anticoagulant Market	340
TABLE 212 GLOBAL ANTICOAGULANT DRUG MARKET, THROUGH 2020 (\$ MILLIONS)	341
FIGURE 37 GLOBAL ANTICOAGULANT DRUG MARKET, 2012-2020 (\$ MILLIONS)	341
Oral Anticoagulants	342
Injectable Anticoagulants	343
Development of New Drugs and Market	343
Antiplatelet Market	344

TOPIC	PAGE NO.
<i>TABLE 213 GLOBAL ANTIPLATELET DRUG MARKET, THROUGH 2020 (\$ MILLIONS)</i>	344
<i>FIGURE 38 GLOBAL ANTIPLATELET DRUG MARKET, 2012-2020 (\$ MILLIONS)</i>	344
Drug Profiles	345
Plavix	345
Generic Versions of Clopidogrel	345
Plavix: History	346
Plavix Market Trends	346
<i>TABLE 214 SOME COMMON ANTIPLATELET AND ANTICOAGULANT</i>	347
Effient/Efient	347
Competition in the Antiplatelet Market	348
<i>TABLE 215 GLOBAL ANTIPLATELET DRUGS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	348
<i>TABLE 216 U.S. SALES OF PLAVIX, 2012 (\$ MILLIONS)</i>	349
Drug Profiles	349
Brilinta	349
Edoxaban/Savaysa/Lixiana	350
Semuloparin	351
Lovenox/Enoxaparin	351
Generic Lovenox	352
<i>TABLE 217 GLOBAL ANTITHROMBOTIC AGENTS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	352
Lovenox History	353
New Drugs	353
Kengrexal	353
Zontivity	354
Market Dynamics	355
Anticoagulant Market	355
Drug Profiles	355
Eliquis	355
Xarelto	356
<i>TABLE 218 XARELTO: APPROVALS IN VENOUS ARTERIAL THROMBOEMBOLIC INDICATIONS</i>	358
Pradaxa	359
Arixtra	359
Activase	359
<i>TABLE 219 GLOBAL ACTIVASE MARKET, THROUGH 2020 (\$ MILLIONS)</i>	360
Angiomax	360
Market Trends for Anticoagulants	360
Warfarin	360
PLATELET AGGREGATION INHIBITORS AND MARKET IMPACT	361
<i>TABLE 220 KEY PLATELET AGGREGATION INHIBITOR DRUG MARKET, 2012 AND 2015 (\$ MILLIONS)</i>	362
<i>TABLE 221 PLATELET AGGREGATION INHIBITORS: PIPELINE DRUGS</i>	363
Cangrelor	363
Heparin Market and Market Dynamics	364
<i>TABLE 222 KEY PLAYERS IN THE GLOBAL HEPARIN MARKET</i>	366
<i>TABLE 223 THROMBOSIS MARKET: PIPELINE DRUGS</i>	367
<i>TABLE 224 PLATELET INHIBITOR: PIPELINE DRUGS</i>	368
NEUTROPENIA TREATMENT MARKET	369

TOPIC	PAGE NO.
TABLE 225 GLOBAL NEUTROPENIA DRUG MARKET, THROUGH 2020 (\$ MILLIONS)	369
FIGURE 39 GLOBAL NEUTROPENIA DRUG MARKET, 2012-2020 (\$ MILLIONS)	369
TABLE 226 COMPANY MARKET SHARES OF KEY NEUTROPENIA DRUGS, 2015 (%)	370
Neulasta (Pegfilgrastim) and Neupogen (Filgrastim)	370
TABLE 227 GROWTH FACTORS FOR TREATING NEUTROPENIA	371
TABLE 228 GLOBAL NEULASTA/NEUPOGEN MARKET, 2012 AND 2015 (\$ MILLIONS)	371
TABLE 229 GLOBAL SARGRAMOSTIM MARKET, 2010 (\$ MILLIONS)	372
Filgrastim Biosimilars	372
TABLE 230 COMPANIES WITH SHORT-ACTING FILGRASTIMS IN PHASE III CLINICAL DEVELOPMENT IN EUROPE	372
TABLE 231 FILGRASTIM PRODUCTS	373
Teva Pharmaceutical	373
Competition in the Neutropenia Market	373
HEMOPHILIA MARKET	374
TABLE 232 GLOBAL HEMOPHILIA THERAPEUTICS MARKET, THROUGH 2020 (\$ MILLIONS)	374
FIGURE 40 GLOBAL HEMOPHILIA THERAPEUTICS MARKET, 2012-2020 (\$ MILLIONS)	374
New Products	375
TABLE 233 GLOBAL KEY HEMOPHILIA PLAYERS	375
Gene Therapy	376
Drugs for the Hemophilia Market	377
TABLE 234 KEY HEMOPHILIA DRUGS	377
TABLE 235 GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, BY TYPE, 2010 (\$ MILLIONS)	377
FIGURE 41 GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, BY TYPE, 2010 (\$ MILLIONS)	378
Market Barriers	378
Drug Pipeline	379
TABLE 236 OTHER COAGULATION PRODUCTS	379
Bayer	380
TABLE 237 GENE THERAPY PROGRAMS IN HEMOPHILIA	380
Other Molecules	381
TABLE 238 FDA APPROVED DRUGS FOR HEMATOLOGY, AUG. 2013-MARCH 2016	382
Advate	384
Biogen Idec	384
Blood Disorders Pipeline	384
TABLE 239 APPROVALS BY HEALTH CANADA, MARCH 2014-JAN. 2016	385
CONCLUSIONS	385
CHAPTER 13 HEMATOLOGICAL CANCER THERAPIES MARKET	388
OVERVIEW	388
TABLE 240 CANCER IN THE UNITED STATES	388
HEMATOLOGICAL CANCERS DRUG MARKET	389
CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES	389
CHRONIC MYELOID DISORDERS	389
GLOBAL CYTOTOXIC THERAPIES MARKET	390
TABLE 241 CYTOTOXIC THERAPIES MARKET INDICATIONS	390
TABLE 242 LIST OF MEDICATIONS	391

TOPIC	PAGE NO.
TABLE 243 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)	393
FIGURE 42 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)	394
U.S. CYTOTHERAPEUTICS MARKET	395
TABLE 244 U.S. CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	395
FIGURE 43 U.S. CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	395
EUROPEAN CYTOTHERAPEUTICS MARKET	396
TABLE 245 EUROPEAN CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	396
FIGURE 44 EUROPEAN CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	396
JAPANESE CYTOTHERAPEUTICS MARKET	397
TABLE 246 JAPANESE CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	397
FIGURE 45 JAPANESE CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	397
LEUKEMIA MARKET AND CHALLENGES	398
TABLE 247 MAJOR LEUKEMIA PLAYERS	398
IS THERE AN UNMET NEED?	399
TABLE 248 RECENT LEUKEMIA INCIDENCE PERCENTAGE BY CATEGORY (%)	399
TABLE 249 GLOBAL LEUKEMIA MARKET, BY TYPE, THROUGH 2020 (\$ MILLIONS)	400
FIGURE 46 GLOBAL LEUKEMIA MARKET, BY TYPE, 2012-2020 (\$ MILLIONS)	401
GLOBAL LEUKEMIA MARKET	401
TABLE 250 LEUKEMIA MARKET SHARE FORECAST, BY COUNTRY, 2011 (%)	402
U.S. Leukemia Market	402
TABLE 251 U.S. LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)	402
FIGURE 47 U.S. LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)	403
European Leukemia Market	403
TABLE 252 EUROPEAN LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)	403
FIGURE 48 EUROPEAN LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)	403
Japanese Leukemia Market	404
TABLE 253 JAPAN'S LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)	404
FIGURE 49 JAPAN'S LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)	404
TABLE 254 GLOBAL LEUKEMIA MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	405
FIGURE 50 GLOBAL LEUKEMIA MARKET BY REGION, 2012-2020 (\$ MILLIONS)	405
CHRONIC MYELOGENOUS LEUKEMIA MARKET	407
TABLE 255 GLOBAL CHRONIC MYELOGENOUS LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)	407
FIGURE 51 GLOBAL CHRONIC MYELOGENOUS LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)	408
MARKET TRENDS AND THERAPEUTIC DRUGS	408
TABLE 256 DRUG CLASSES' FOR LEUKEMIA DRUG DEVELOPMENT	409
TABLE 257 KEY CHRONIC MYELOGENOUS LEUKEMIA MARKET, BY DRUG, 2010-2015 (\$ MILLIONS)	410
FIGURE 52 KEY CHRONIC MYELOGENOUS LEUKEMIA MARKET, BY DRUG, 2010-2015 (\$ MILLIONS)	410
Market Trends	411
Therapeutic Drugs	411
Gleevec	411
TABLE 258 KEY CML MEDICINES AND COST	412
TABLE 259 GLEEVAC FDA APPROVALS, 2002-2012	412
Tasigna	413
Sprycel	414

TOPIC	PAGE NO.
Combination Treatment	414
New Drugs for CML	414
Drug Profiles	416
Bosulif	416
Synribo	416
Bafetinib	417
Rebastinib/DCC-2036	418
Danusertib	418
<i>TABLE 260 RECENT PIPELINE DRUGS FOR LEUKEMIA</i>	418
Ponatinib	419
ACUTE LYMPHOCYTIC LEUKEMIA MARKET	420
<i>TABLE 261 GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	420
<i>FIGURE 53 GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, 2012-2020 (\$ MILLIONS)</i>	420
<i>TABLE 262 MAJOR ACUTE LYMPHOCYTIC LEUKEMIA PLAYERS IN THE MARKET</i>	421
ACUTE LYMPHOCYTIC LEUKEMIA AND CHILDREN THERAPEUTICS	421
<i>TABLE 263 DRUGS FOR ACUTE LYMPHOCYTIC LEUKEMIA (ALL) TREATMENT</i>	422
Clolar	422
Oncaspar	422
Nelarabine	423
Marqibo	424
<i>TABLE 264 APPROVED DRUGS FOR ALL</i>	424
Graspa	424
ACUTE MYELOID LEUKEMIA (AML) MARKET	425
<i>TABLE 265 GLOBAL ACUTE MYELOID LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)</i>	426
<i>FIGURE 54 GLOBAL ACUTE MYELOID LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)</i>	426
THERAPEUTIC DRUGS	427
Elacytarabine	428
Quizartinib	428
KEY COMPANIES	429
<i>TABLE 266 KEY COMPANIES IN THE AML MARKET</i>	429
NEW DEVELOPMENTS	429
Astex Pharmaceuticals	430
ACUTE MYELOID LEUKEMIA AND CHILDREN Treatment Costs	431
CHRONIC LYMPHOCYTIC LEUKEMIA MARKET	432
<i>TABLE 267 GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)</i>	432
<i>FIGURE 55 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)</i>	432
THERAPEUTIC DRUGS	433
Arzerra	433
<i>TABLE 268 GLOBAL ARZERRA MARKET, 2010-2015 (\$ MILLIONS)</i>	433
Fludara	434
Campath	434
Treanda	435

TOPIC	PAGE NO.
<i>TABLE 269 GLOBAL TREANDA MARKET, 2014-2017 (\$ MILLIONS)</i>	435
PIPELINE	436
Venetoclax	436
NOX-A12 anti-CXCL12/SDF-1/Spiegelmer	437
<i>TABLE 270 NOX-A12: HOW DOES IT WORK?</i>	438
Imbruvica/Ibrutinib	439
Idelalisib/GS-1101	440
<i>TABLE 271 GILEAD: HEMATOLOGY AND ONCOLOGY PIPELINE</i>	441
NEW DEVELOPMENTS	441
Blinatumomab	441
NEW DRUGS IN DEVELOPMENT	442
Combining the Targeted Drugs with Other Treatments	442
NEW DRUGS FOR CML	442
CANCER VACCINES	443
LYMPHOMA DRUG MARKET	443
MARKET TRENDS	443
<i>TABLE 272 GENERIC DRUGS USED IN COMBINATION TO TREAT HODGKIN LYMPHOMA</i>	443
<i>TABLE 273 DRUGS USED IN COMBINATION TO TREAT NON-HODGKIN LYMPHOMA</i>	444
CHEMOTHERAPY	445
BONE MARROW AND PERIPHERAL BLOOD STEM CELL TRANSPLANTS	445
TARGETED THERAPIES	445
Antibiotics	445
Monoclonal Antibodies	446
Lymphoma Vaccines	446
Idelalisib	447
NON-HODGKIN LYMPHOMA DRUG MARKET	447
<i>TABLE 274 GLOBAL NON-HODGKIN LYMPHOMA DRUG MARKET, THROUGH 2020 (\$ MILLIONS)</i>	447
<i>FIGURE 56 GLOBAL NON-HODGKIN LYMPHOMA DRUG MARKET, 2012-2020 (\$ MILLIONS)</i>	448
Rituximab	448
<i>TABLE 275 GLOBAL RITUXIMAB MARKET, 2010-2015 (\$ MILLIONS)</i>	448
Rituxan Biosimilars Development and Key Companies	449
<i>TABLE 276 RITUXAN: BIOSIMILARS IN DEVELOPMENT</i>	450
New Drugs	451
Revlimid	451
<i>TABLE 277 GLOBAL REVLIMID MARKET, 2011-2015 (\$ MILLIONS)</i>	451
HODGKIN LYMPHOMA TREATMENT MARKET	453
<i>TABLE 278 GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET, THROUGH 2020 (\$ MILLIONS)</i>	453
<i>FIGURE 57 GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET, 2012-2020 (\$ MILLIONS)</i>	453
Market Dynamics and Pipeline	453
Adcetris/Brentuximab Vedotin	454
Farydak/Panobinostat	455
MULTIPLE MYELOMA TREATMENT MARKET	456
<i>TABLE 279 GLOBAL MULTIPLE MYELOMA TREATMENT MARKET, THROUGH 2020 (\$ MILLIONS)</i>	457

TOPIC	PAGE NO.
<i>FIGURE 58 GLOBAL MULTIPLE MYELOMA TREATMENT MARKET, 2012-2020 (\$ MILLIONS)</i>	457
<i>TABLE 280 DRUGS FOR THE MYELOMA MARKET</i>	458
THERAPEUTIC DRUGS	458
Kyprolis	458
Revlimid	459
Velcade	460
Pomalidomide	460
PIPELINE DRUG CANDIDATES	460
<i>TABLE 281 PIPELINE DRUGS FOR MYELOMA IN DEVELOPMENT</i>	461
Obatoclox	461
Perifosine	461
Panobinostat (Faridak)	461
Aplidin	462
Treanda	462
<i>TABLE 282 TREANDA CLINICAL TRIALS IN RELAPSED AND/OR REFRACTORY MYELOMA</i>	462
MYELOYDYSPLASTIC SYNDROME MARKET	462
<i>TABLE 283 GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET, THROUGH 2020 (\$ MILLIONS)</i>	463
<i>FIGURE 59 GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET, 2012-2020 (\$ MILLIONS)</i>	463
MDS THERAPIES	463
<i>TABLE 284 APPROVED DRUGS FOR THE TREATMENT OF MDS</i>	464
Decitabine	464
Vidaza	464
PIPELINE	465
<i>TABLE 285 DRUGS IN CLINICAL DEVELOPMENT</i>	465
MYELOPROLIFERATIVE DISORDERS	465
<i>TABLE 286 GLOBAL MYELOPROLIFERATIVE DISORDERS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	466
<i>FIGURE 60 GLOBAL MYELOPROLIFERATIVE DISORDERS MARKET, 2012-2020 (\$ MILLIONS)</i>	466
MARKET TRENDS	467
<i>TABLE 287 JAK2 INHIBITORS IN DEVELOPMENT</i>	467
THERAPEUTIC DRUGS	468
Jakafi/Ruxolitinib	468
<i>TABLE 288 GLOBAL JAKAFI/RUXOLITINIB MARKET, THROUGH 2020 (\$ MILLIONS)</i>	468
TG101348	469
AZD1480	469
R723	469
XL019	470
CYT387	470
SB1518	470
MARKET FOR ESSENTIAL THROMBOCYTOSIS (ET)	471
MYELOFIBROSIS MARKET	471
<i>TABLE 289 GLOBAL MYELOFIBROSIS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	471
<i>FIGURE 61 GLOBAL MYELOFIBROSIS MARKET, 2012-2020 (\$ MILLIONS)</i>	471
TREATMENT OPTIONS FOR MYELOFIBROSIS	472

TOPIC	PAGE NO.
POLYCYTHEMIA VERA (PV) THERAPEUTICS MARKET	472
TABLE 290 GLOBAL POLYCYTHEMIA VERA MARKET, THROUGH 2020 (\$ MILLIONS)	472
FIGURE 62 GLOBAL POLYCYTHEMIA VERA MARKET, 2012-2020 (\$ MILLIONS)	473
TREATMENT EXPENSE	473
CHAPTER 14 PATENT LANDSCAPE AND CURRENT DEVELOPMENTS	475
TABLE 291 MAJOR BLOOD DISORDER DRUG PATENT EXPIRIES, 2009-2015	475
TABLE 292 KEY BLOOD DISORDER DRUGS: PATENT EXPIRY	476
TABLE 293 DRUGS LOSING PATENT PROTECTION BY 2015, GLOBAL SALES 2010 (\$ MILLIONS)	476
HEMATOLOGICAL CANCER DRUG PATENT EXPIRIES	477
TABLE 294 BIOLOGIC DRUG PATENT EXPIRIES	477
NEW APPROVALS	479
TABLE 295 NEW DRUG APPROVALS FOR BLOOD DISORDERS, 2012	479
NEW HEMATOLOGICAL CANCER DRUGS	479
TABLE 296 NEW DRUG APPROVALS FOR HEMATOLOGICAL CANCERS, 2012	480
NEWS AND DEVELOPMENTS	481
Type 2 Diabetes Linked to Increased Blood Cancer Risk	481
NOVARTIS AND PATENT ISSUES	482
DRUGS IN DEVELOPMENT	482
Ariad Pharmaceuticals	482
Pharmacyclics	482
AiCuris	483
Cell Therapeutics	483
Biogen Idec/Swedish Orphan Biovitrum	483
Inspiration Biopharmaceuticals	483
Novartis	484
Merck	484
The Medicines Co.	484
Isis Pharmaceuticals	485
CytoPharm and Amarillo Biosciences	485
SuppreMol	485
MorphoSys and Xencor	485
ARIAD Pharmaceuticals	486
OTHER DEVELOPMENTS	486
Universal Cancer Blood Test	486
Boehringer Ingelheim	487
Janssen Biotech	488
Mergers	488
Blood Disorders News	488
AMAG Pharmaceuticals	488
Affymax vs. Amgen	489
ACQUISITIONS	490
Gilead Sciences	490
CHAPTER 15 SELECTED COMPANY PROFILES	492
ABBOTT LABORATORIES	492
ABON PHARMACEUTICALS	492

TOPIC	PAGE NO.
AMBIT BIOSCIENCES	492
AMGEN	493
AMPHASTAR PHARMACEUTICALS	493
ARIAD PHARMACEUTICALS	493
ASTELLAS PHARMA US	494
ASTEX PHARMACEUTICALS	494
ASTRAZENECA	494
BAXALTA INC.	495
BAXTER HEALTHCARE CORP.	495
BAYER HEALTHCARE PHARMACEUTICALS	496
BIOGEN IDEC	496
BOEHRINGER INGELHEIM GMBH	496
BRISTOL-MYERS SQUIBB	497
CELGENE CORP.	497
CHUGAI PHARMACEUTICAL	498
C.R. BARD	498
CZ BIOMED CORP.	498
DAIICHI SANKYO CO. LTD.	499
DECIPHERA PHARMACEUTICALS	499
DIAGNOCURE	499
EISAI INC.	500
ELI LILLY AND CO.	500
ENZON PHARMACEUTICALS	500
ERYTECH PHARMA SA	501
EXELIXIS	502
GE HEALTHCARE	502
GENENTECH INC.	503
GENMAB INC.	503
GILEAD SCIENCES	504
GLAXOSMITHKLINE	504
HOLOGIC	504
HORIBA LTD.	505
JOHNSON & JOHNSON	505
THE MEDICINES CO.	506
MEDKOO BIOSCIENCES	506
MOMENTA PHARMACEUTICALS	506
NOXXON PHARMA AG	507
PORTOLA PHARMACEUTICALS INC.	507
OPKO HEALTH	507
OTSUKA PHARMACEUTICAL	508
PFIZER	508
PHARMACYCLICS	509
ROCHE DIAGNOSTICS	509
SANDOZ INTERNATIONAL GMBH	509
SANOFI	510
SIEMENS AG	510
SPECTRUM PHARMACEUTICALS	510

TOPIC	PAGE NO.
TEVA PHARMACEUTICAL INDUSTRIES LTD.	511
WATSON PHARMACEUTICALS INC.	511
YM BIOSCIENCES INC.	511
CHAPTER 16 BIBLIOGRAPHY	514

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS, BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	8
TABLE 1 KEY BLOOD DISORDERS	11
TABLE 2 MALIGNANT BLOOD DISORDERS	11
TABLE 3 NONMALIGNANT BLOOD DISORDERS	12
TABLE 4 TYPE OF BLOOD CELLS AND FUNCTIONS	13
TABLE 5 COMPONENTS OF BLOOD	14
TABLE 6 THREE MAJOR TYPES OF ANEMIA	15
TABLE 7 CAUSES OF ANEMIA	15
TABLE 8 SYMPTOMS OF ANEMIA	16
TABLE 9 ANEMIA: TYPES, CAUSES AND TREATMENT	17
TABLE 10 DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY BY CLASS	19
TABLE 11 DRUGS THAT CAN CAUSE FOLATE DEFICIENCY	20
TABLE 12 SICKLE CELL ANEMIA: KEY FACTS	23
TABLE 13 LAB TESTS FOR ANEMIA	24
TABLE 14 HEMOSTASIS: THREE MAJOR STEPS	27
TABLE 15 DRUGS THAT AFFECT THE ACTIVITY OF PLATELETS	29
TABLE 16 ANTICOAGULANTS THAT ACT ON THROMBIN	29
TABLE 17 BLEEDING DISORDERS	30
TABLE 18 SYMPTOMS OF BLEEDING DISORDERS	31
TABLE 19 SIGNS AND TESTS FOR BLEEDING DISORDERS	31
TABLE 20 KEY CHARACTERISTICS OF HEMOPHILIA	32
TABLE 21 FVIII INHIBITORS	40
TABLE 22 MEDICATIONS FOR TREATING HEMOPHILIA	41
TABLE 23 FACTOR VIII PRODUCTS	42
TABLE 24 ANTIFIBRINOLYTICS BY DRUG	42
TABLE 25 ANTIHEMOPHILIC AGENTS BY CLASS	43
TABLE 26 FORMATION OF THROMBUS	47
TABLE 27 CAUSES OF NEUTROPENIA	53
TABLE 28 WHITE BLOOD CELL DISORDERS	55
TABLE 29 CAUSES OF SECONDARY THROMBOCYTOSIS	59
TABLE 30 DIAGNOSTIC TESTS FOR THROMBOCYTHEMIA	60
TABLE 31 MEDICINES FOR THROMBOCYTHEMIA	61
TABLE 32 CAUSES OF THROMBOCYTOPENIA	62
TABLE 33 SIGNS OF EXTERNAL BLEEDING	63
TABLE 34 COMMON DRUGS TO TREAT EOSINOPHILIA	65
TABLE 35 HEMATOLOGICAL CANCERS (BLOOD CANCERS)	68
TABLE 36 RELATIVE OCCURRENCE OF HEMATOLOGICAL MALIGNANCIES IN THE U.S., 2016 (NUMBER/%)	69
TABLE 37 TYPES OF HEMATOLOGICAL CANCERS	70
TABLE 38 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2014-2016	74
TABLE 39 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2012	77
TABLE 40 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2011	78
TABLE 41 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 1996-2010	79

TABLE HEADING	PAGE NO.
TABLE 42 TYPES OF LEUKEMIA	84
TABLE 43 TYPES OF LEUKEMIA AND KEY FEATURES	85
TABLE 44 DIAGNOSTIC EXAMS FOR LEUKEMIA	89
TABLE 45 ADDITIONAL TESTS	89
TABLE 46 PCR TESTS	92
TABLE 47 NON-LABORATORY TESTS	92
TABLE 48 COMMON TREATMENTS USED TO FIGHT LEUKEMIA	93
TABLE 49 NEWER CLASSES OF DRUGS	94
TABLE 50 ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT	96
TABLE 51 DRUGS APPROVED FOR ACUTE LYMPHOBLASTIC LEUKEMIA	97
TABLE 52 DRUGS APPROVED FOR CHRONIC LYMPHOCYTIC LEUKEMIA	98
TABLE 53 DRUGS APPROVED FOR ACUTE MYELOID LEUKEMIA	99
TABLE 54 DRUGS APPROVED FOR CHRONIC MYELOGENOUS LEUKEMIA	100
TABLE 55 T-CELL PROLYMPHOCYTIC LEUKEMIA: TREATMENT PLAN	101
TABLE 56 FACTORS AFFECTING LEUKEMIA STAGING AND PROGNOSIS	102
TABLE 57 CHEMOTHERAPY DRUGS FOR CML	104
TABLE 58 CHEMOTHERAPY DRUGS FOR CLL	104
TABLE 59 TARGETED THERAPY DRUGS	105
TABLE 60 ADVANTAGES OF RADIOIMMUNOTHERAPY	106
TABLE 61 COMMON RADIATION TREATMENTS: LEUKEMIA	106
TABLE 62 PAIN MEDICATIONS	108
TABLE 63 EMERGING THERAPIES FOR LEUKEMIA	108
TABLE 64 CAUSES OF LYMPHOMA	113
TABLE 65 LYMPHOMA TYPES	114
TABLE 66 STAGING FOR HL AND NHL TUMORS	116
TABLE 67 MATURE B-CELL NEOPLASMS	117
TABLE 68 MATURE T-CELL AND NATURAL KILLER CELL NEOPLASMS	117
TABLE 69 HODGKIN LYMPHOMA	118
TABLE 70 IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS	118
TABLE 71 SYMPTOMS OF NON-HODGKIN LYMPHOMA	119
TABLE 72 FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS: NON HODGKIN LYMPHOMA, 2006-2012 (%)	119
TABLE 73 IMAGING TESTS FOR LYMPHOMA	120
TABLE 74 THE INTERNATIONAL PROGNOSTIC INDEX FOR HL	121
TABLE 75 THE INTERNATIONAL PROGNOSTIC INDEX FOR NHL	122
TABLE 76 PROMISING THERAPIES FOR TREATING LYMPHOMA	124
TABLE 77 PROGNOSTIC INDICATORS FOR MYELOMA	132
TABLE 78 OTHER BONE MARROW TESTS	132
TABLE 79 MYELOMA: STAGING CRITERIA	134
TABLE 80 MYELOMA'S RESPONSE TO TREATMENT	135
TABLE 81 SUPPORTIVE CARE FOR MYELOMA	138
TABLE 82 DRUGS FOR MULTIPLE MYELOMA	140
TABLE 83 NEW AND EMERGING THERAPIES FOR MYELOMA	141
TABLE 84 CHARACTERISTICS OF MDS	147
TABLE 85 CAUSES OF MDS	148
TABLE 86 MDS OR AML: THREE CATEGORIES	148
TABLE 87 MYELOYDYSPLASTIC SYNDROMES: KEY FACTS	149
TABLE 88 FAB CLASSIFICATION OF MDS	150

TABLE HEADING	PAGE NO.
TABLE 89 THE 2008 WHO CLASSIFICATION OF MDS	151
TABLE 90 INTERNATIONAL PROGNOSTIC SCORING SYSTEM RISK GROUPS AND PROGNOS (YEARS)	152
TABLE 91 CHANGES IN CELLS DUE TO MDS	153
TABLE 92 CHRONIC MYELOPROLIFERATIVE DISORDERS	163
TABLE 93 CLASSIFICATION OF MYELOID NEOPLASMS ACCORDING TO THE 2008 WHO CLASSIFICATION SCHEME	167
TABLE 94 MYELOPROLIFERATIVE NEOPLASMS: KEY FACTS	169
TABLE 95 DIAGNOSTIC TESTS	170
TABLE 96 SYMPTOMS OF POLYCYTHEMIA VERA	171
TABLE 97 BLOOD TESTS FOR POLYCYTHEMIA VERA	172
TABLE 98 TREATMENT FOR POLYCYTHEMIA VERA	173
TABLE 99 CAUSATIVE FACTORS FOR MYELOFIBROSIS	175
TABLE 100 POTENTIAL COMPLICATIONS FROM MYELOFIBROSIS	175
TABLE 101 WHO DIAGNOSTIC CRITERIA FOR PMF	177
TABLE 102 RISK FACTORS	178
TABLE 103 IDIOPATHIC MYELOFIBROSIS AND SYMPTOMS	178
TABLE 104 PROGNOSIS FACTORS	179
TABLE 105 TREATMENT OF CHRONIC IDIOPATHIC MYELOFIBROSIS	181
TABLE 106 SOMATIC MUTATIONS	183
TABLE 107 CAUSES OF THROMBOCYTOSIS	184
TABLE 108 SYMPTOMS OF ESSENTIAL THROMBOCYTOSIS	185
TABLE 109 ESSENTIAL THROMBOCYTHEMIA: DIAGNOSTIC CRITERIA	186
TABLE 110 TREATMENT OF ET	189
TABLE 111 TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA	192
TABLE 112 SYMPTOMS OF CHRONIC EOSINOPHILIC LEUKEMIA	193
TABLE 113 TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA	193
TABLE 114 CURRENT DRUGS	196
TABLE 115 CANCER KEY FACTS	199
TABLE 116 INCREASE IN CANCER BURDEN: FACTORS	200
TABLE 117 GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO./%)	203
TABLE 118 GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO.)	203
TABLE 119 GLOBAL INCIDENCE OF BLOOD CANCERS IN MEN, 2012 (NO./%)	204
TABLE 120 GLOBAL INCIDENCE OF BLOOD CANCERS IN WOMEN, 2012 (NO./%)	204
TABLE 121 TOP 10 COUNTRIES' CANCER INCIDENCE RATES (PER 100,000 POPULATION)	205
TABLE 122 ESTIMATED INCIDENCE OF BLOOD CANCERS IN THE U.S., 2011 VS. 2016 (PER 100,000 POPULATION)	206
TABLE 123 ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2016 (NO.)	208
TABLE 124 ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)	209
TABLE 125 GLOBAL INCIDENCE OF LEUKEMIA, 2012 (NUMBER/%)	213
TABLE 126 U.S. LEUKEMIA INCIDENCE STATISTICS, 2012	214
TABLE 127 ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S., 2010-2016 (NO.)	214
TABLE 128 ESTIMATED NEW CASES OF LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2016	215

TABLE HEADING	PAGE NO.
TABLE 129 ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008 (NO.)	216
TABLE 130 PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.)	217
TABLE 131 TYPES OF LEUKEMIA IN ADULTS IN THE U.S. AND AGE GROUP	219
TABLE 132 ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE, 2012 (NO.)	219
TABLE 133 AGE-ADJUSTED INCIDENCE RATES OF LEUKEMIA IN THE U.S. BY RACE, SEER 18, 2009-2013 (PER 100,000 POPULATION)	221
TABLE 134 FIVE-YEAR RELATIVE SURVIVAL RATES IN THE U.S. FOR LEUKEMIA, 2005-2011 (%)	221
TABLE 135 ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO.)	222
TABLE 136 NEW CASES OF LEUKEMIA IN THE U.K., 2013 (NO.)	223
TABLE 137 GLOBAL ESTIMATES OF LEUKEMIA DEATHS/MORTALITY RATES, 2012	227
TABLE 138 GLOBAL ESTIMATED INCIDENCE RATES OF NON-HODGKIN LYMPHOMA FOR ALL AGES AND BOTH SEXES, 2012	230
TABLE 139 GLOBAL ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES BY ALL AGES AND BOTH SEXES, 2012	231
TABLE 140 GLOBAL ESTIMATED INCIDENCE OF HODGKIN LYMPHOMA FOR ALL AGES AND BOTH SEXES, 2012	233
TABLE 141 ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)	234
TABLE 142 ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)	236
TABLE 143 ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES IN EU-27 COUNTRIES, 2012 (ESTIMATED RATES PER 100,000 POPULATION)	238
TABLE 144 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)	240
TABLE 145 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2012 (NO.)	242
TABLE 146 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE, 2011-2016 (NO.)	243
TABLE 147 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2012 (NO.)	244
TABLE 148 ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2011 (NO.)	245
TABLE 149 U.S. AGE-SPECIFIC NHL INCIDENCE RATES BY GENDER (ESTIMATED RATES PER 100,000 POPULATION)	245
TABLE 150 U.S. LYMPHOMA INCIDENCE RATES BY RACE, 2005-2009 (PER 100,000 POPULATION)	246
TABLE 151 U.S. LYMPHOMA MORTALITY RATES BY RACE, 2005-2009 (PER 100,000 POPULATION)	246
TABLE 152 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACES, BOTH SEXES BY STAGE AT DIAGNOSIS, 2002-2008 (%)	249
TABLE 153 NEW CASES OF NON-HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.)	250
TABLE 154 NON-HODGKIN LYMPHOMA DEATHS IN THE U.K. BY SEX, 2012 (NO.)	253
TABLE 155 ESTIMATED NUMBER OF NEW CASES OF HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.)	254
TABLE 156 ESTIMATED NUMBER OF DEATHS FROM HODGKIN'S LYMPHOMA IN THE U.K., 2012 (NO.)	255
TABLE 157 ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER 100,000 POPULATION)	257

TABLE HEADING	PAGE NO.
TABLE 158 ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, 2008 (PER 100,000 POPULATION)	259
TABLE 159 ESTIMATED INCIDENCE OF MYELOMA IN EU-27 COUNTRIES, 2012 (NO.)	261
TABLE 160 DEATHS FROM MYELOMA IN EU-27 COUNTRIES, 2012 (NO.)	263
TABLE 161 ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016 (NO.)	264
TABLE 162 ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S., 2011-2016 (NO.)	265
TABLE 163 AGE-ADJUSTED INCIDENCE RATES OF MYELOMA IN THE U.S. BY RACE, SEER 18 2009-2013 (PER 100,000 POPULATION)	267
TABLE 164 AGE-ADJUSTED DEATH RATES FROM MYELOMA IN THE U.S. BY RACE, SEER 18 2009-2013 (PER 100,000 POPULATION)	268
TABLE 165 DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL FOR ALL AGES AND BOTH SEXES IN THE U.S. BY STAGE AT DIAGNOSIS, 2002-2008 (%)	268
TABLE 166 NEW CASES OF MYELOMA IN THE U.K., 2013 (NO.)	270
TABLE 167 MYELOMA DEATHS IN THE U.K., 2012 (NO.)	271
TABLE 168 ESTIMATED NEW CASES OF MDS IN THE U.S., 2012 (NO.)	273
TABLE 169 KEY FACTORS DRIVING THE GROWTH OF THE HEMATOLOGICAL DISORDERS MARKET	283
TABLE 170 GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2020 (\$ MILLIONS)	284
TABLE 171 KEY HEMATOLOGY PRODUCTS	286
TABLE 172 GLOBAL MAJOR COMPANIES IN THE HEMATOLOGY MARKET	287
TABLE 173 KEY PLAYERS IN FLOW CYTOMETRY	289
TABLE 174 GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2020 (\$ MILLIONS)	290
TABLE 175 MAJOR FLOW CYTOMETRY APPLICATIONS	291
TABLE 176 CELL ANALYZERS	292
TABLE 177 HEMATOLOGY TESTS	294
TABLE 178 COMPLETE BLOOD COUNT: COMPONENTS MEASURED	295
TABLE 179 TESTS INCLUDED IN A CHEMISTRY SCREEN	297
TABLE 180 CHEMISTRY SCREEN	297
TABLE 181 URINE TESTS AND APPLICATIONS	299
TABLE 182 GLOBAL IVD PRODUCTS MARKET, THROUGH 2020 (\$ MILLIONS)	301
TABLE 183 U.S. IVD MARKET, THROUGH 2020 (\$ MILLIONS)	302
TABLE 184 GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, THROUGH 2020 (\$ MILLIONS)	303
TABLE 185 GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, THROUGH 2020 (\$ MILLIONS)	304
TABLE 186 KEY PLAYERS IN THE IMMUNOASSAYS MARKET	305
TABLE 187 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2020 (\$ MILLIONS)	306
TABLE 188 MAJOR PLAYERS IN MOLECULAR DIAGNOSTICS MARKET	307
TABLE 189 GLOBAL POINT-OF-CARE TESTING MARKET, THROUGH 2020 (\$ MILLIONS)	308
TABLE 190 POC TESTING KITS	309
TABLE 191 GLOBAL MARKET FOR POC TESTS, THROUGH 2020 (\$ MILLIONS)	309
TABLE 192 GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, THROUGH 2020 (\$ MILLIONS)	311
TABLE 193 TYPES OF CARDIAC MARKERS	312
TABLE 194 KEY MARKET PLAYERS IN THE BLOOD SCREENING MARKET	314

TABLE HEADING	PAGE NO.
TABLE 195 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS, BY TYPE, THROUGH 2020 (\$ MILLIONS)	316
TABLE 196 GLOBAL MARKET SHARES OF TREATMENTS FOR HEMATOLOGICAL DISORDERS BY TYPE, 2015 AND 2020 (%)	317
TABLE 197 PATENT EXPIRIES OF MAJOR BLOCKBUSTERS DRUGS	318
TABLE 198 GLOBAL KEY PLAYERS OF HEMATOLOGICAL DISORDERS MARKET BY PRODUCTS AND MARKET SHARE, 2015 (%)	318
TABLE 199 MARKET DRIVERS OF HEMATOLOGICAL DISORDERS	319
TABLE 200 MARKET RESTRAINTS OF HEMATOLOGICAL DISORDERS	319
TABLE 201 GLOBAL ANEMIA TREATMENT MARKET, THROUGH 2020 (\$ MILLIONS)	320
TABLE 202 TYPES OF ANEMIA	320
TABLE 203 COMMON ANEMIA TREATMENTS	321
TABLE 204 ERYTHROPOIETIN STIMULATING AGENTS	322
TABLE 205 KEY ANEMIA DRUGS SALES, 2012 AND 2015 (\$ MILLIONS)	323
TABLE 206 GLOBAL NEORECORMON MARKET, 2010-2015* (\$ MILLIONS)	325
TABLE 207 GLOBAL NEORECORMON MARKET, 2009 (\$ MILLIONS)	326
TABLE 208 BIOSIMILARS OF EPOETIN ALFA AND DARBEPOETIN ALFA	327
TABLE 209 AKEBIA THERAPEUTICS: ANEMIA DRUG IN DEVELOPMENT-AKB-6548	337
TABLE 210 GLOBAL ANTITHROMBOTIC DRUG MARKET, BY TYPE, THROUGH 2020 (\$ MILLIONS)	338
TABLE 211 LEADING DRUGS IN THE ANTITHROMBOTIC AGENTS MARKET	339
TABLE 212 GLOBAL ANTICOAGULANT DRUG MARKET, THROUGH 2020 (\$ MILLIONS)	341
TABLE 213 GLOBAL ANTIPLATELET DRUG MARKET, THROUGH 2020 (\$ MILLIONS)	344
TABLE 214 SOME COMMON ANTIPLATELET AND ANTICOAGULANT	347
TABLE 215 GLOBAL ANTIPLATELET DRUGS MARKET, THROUGH 2020 (\$ MILLIONS)	348
TABLE 216 U.S. SALES OF PLAVIX, 2012 (\$ MILLIONS)	349
TABLE 217 GLOBAL ANTITHROMBOTIC AGENTS MARKET, THROUGH 2020 (\$ MILLIONS)	352
TABLE 218 XARELTO: APPROVALS IN VENOUS ARTERIAL THROMBOEMBOLIC INDICATIONS	358
TABLE 219 GLOBAL ACTIVASE MARKET, THROUGH 2020 (\$ MILLIONS)	360
TABLE 220 KEY PLATELET AGGREGATION INHIBITOR DRUG MARKET, 2012 AND 2015 (\$ MILLIONS)	362
TABLE 221 PLATELET AGGREGATION INHIBITORS: PIPELINE DRUGS	363
TABLE 222 KEY PLAYERS IN THE GLOBAL HEPARIN MARKET	366
TABLE 223 THROMBOSIS MARKET: PIPELINE DRUGS	367
TABLE 224 PLATELET INHIBITOR: PIPELINE DRUGS	368
TABLE 225 GLOBAL NEUTROPENIA DRUG MARKET, THROUGH 2020 (\$ MILLIONS)	369
TABLE 226 COMPANY MARKET SHARES OF KEY NEUTROPENIA DRUGS, 2015 (%)	370
TABLE 227 GROWTH FACTORS FOR TREATING NEUTROPENIA	371
TABLE 228 GLOBAL NEULASTA/NEUPOGEN MARKET, 2012 AND 2015 (\$ MILLIONS)	371
TABLE 229 GLOBAL SARGRAMOSTIM MARKET, 2010 (\$ MILLIONS)	372
TABLE 230 COMPANIES WITH SHORT-ACTING FILGRASTIMS IN PHASE III CLINICAL DEVELOPMENT IN EUROPE	372
TABLE 231 FILGRASTIM PRODUCTS	373
TABLE 232 GLOBAL HEMOPHILIA THERAPEUTICS MARKET, THROUGH 2020 (\$ MILLIONS)	374
TABLE 233 GLOBAL KEY HEMOPHILIA PLAYERS	375
TABLE 234 KEY HEMOPHILIA DRUGS	377

TABLE HEADING	PAGE NO.
TABLE 235 GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, BY TYPE, 2010 (\$ MILLIONS)	377
TABLE 236 OTHER COAGULATION PRODUCTS	379
TABLE 237 GENE THERAPY PROGRAMS IN HEMOPHILIA	380
TABLE 238 FDA APPROVED DRUGS FOR HEMATOLOGY, AUG. 2013-MARCH 2016	382
TABLE 239 APPROVALS BY HEALTH CANADA, MARCH 2014-JAN. 2016	385
TABLE 240 CANCER IN THE UNITED STATES	388
TABLE 241 CYTOTOXIC THERAPIES MARKET INDICATIONS	390
TABLE 242 LIST OF MEDICATIONS	391
TABLE 243 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)	393
TABLE 244 U.S. CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	395
TABLE 245 EUROPEAN CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	396
TABLE 246 JAPANESE CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	397
TABLE 247 MAJOR LEUKEMIA PLAYERS	398
TABLE 248 RECENT LEUKEMIA INCIDENCE PERCENTAGE BY CATEGORY (%)	399
TABLE 249 GLOBAL LEUKEMIA MARKET, BY TYPE, THROUGH 2020 (\$ MILLIONS)	400
TABLE 250 LEUKEMIA MARKET SHARE FORECAST, BY COUNTRY, 2011 (%)	402
TABLE 251 U.S. LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)	402
TABLE 252 EUROPEAN LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)	403
TABLE 253 JAPAN'S LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)	404
TABLE 254 GLOBAL LEUKEMIA MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	405
TABLE 255 GLOBAL CHRONIC MYELOGENOUS LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)	407
TABLE 256 DRUG CLASSES' FOR LEUKEMIA DRUG DEVELOPMENT	409
TABLE 257 KEY CHRONIC MYELOGENOUS LEUKEMIA MARKET, BY DRUG, 2010-2015 (\$ MILLIONS)	410
TABLE 258 KEY CML MEDICINES AND COST	412
TABLE 259 GLEEVAC FDA APPROVALS, 2002-2012	412
TABLE 260 RECENT PIPELINE DRUGS FOR LEUKEMIA	418
TABLE 261 GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, THROUGH 2020 (\$ MILLIONS)	420
TABLE 262 MAJOR ACUTE LYMPHOCYTIC LEUKEMIA PLAYERS IN THE MARKET	421
TABLE 263 DRUGS FOR ACUTE LYMPHOCYTIC LEUKEMIA (ALL) TREATMENT	422
TABLE 264 APPROVED DRUGS FOR ALL	424
TABLE 265 GLOBAL ACUTE MYELOID LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)	426
TABLE 266 KEY COMPANIES IN THE AML MARKET	429
TABLE 267 GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, THROUGH 2020 (\$ MILLIONS)	432
TABLE 268 GLOBAL ARZERRA MARKET, 2010-2015 (\$ MILLIONS)	433
TABLE 269 GLOBAL TREANDA MARKET, 2014-2017 (\$ MILLIONS)	435
TABLE 270 NOX-A12: HOW DOES IT WORK?	438
TABLE 271 GILEAD: HEMATOLOGY AND ONCOLOGY PIPELINE	441
TABLE 272 GENERIC DRUGS USED IN COMBINATION TO TREAT HODGKIN LYMPHOMA	443
TABLE 273 DRUGS USED IN COMBINATION TO TREAT NON-HODGKIN LYMPHOMA	444
TABLE 274 GLOBAL NON-HODGKIN LYMPHOMA DRUG MARKET, THROUGH 2020 (\$ MILLIONS)	447
TABLE 275 GLOBAL RITUXIMAB MARKET, 2010-2015 (\$ MILLIONS)	448
TABLE 276 RITUXAN: BIOSIMILARS IN DEVELOPMENT	450

TABLE HEADING	PAGE NO.
TABLE 277 GLOBAL REVLIMID MARKET, 2011-2015 (\$ MILLIONS)	451
TABLE 278 GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET, THROUGH 2020 (\$ MILLIONS)	453
TABLE 279 GLOBAL MULTIPLE MYELOMA TREATMENT MARKET, THROUGH 2020 (\$ MILLIONS)	457
TABLE 280 DRUGS FOR THE MYELOMA MARKET	458
TABLE 281 PIPELINE DRUGS FOR MYELOMA IN DEVELOPMENT	461
TABLE 282 TREANDA CLINICAL TRIALS IN RELAPSED AND/OR REFRACTORY MYELOMA	462
TABLE 283 GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET, THROUGH 2020 (\$ MILLIONS)	463
TABLE 284 APPROVED DRUGS FOR THE TREATMENT OF MDS	464
TABLE 285 DRUGS IN CLINICAL DEVELOPMENT	465
TABLE 286 GLOBAL MYELOPROLIFERATIVE DISORDERS MARKET, THROUGH 2020 (\$ MILLIONS)	466
TABLE 287 JAK2 INHIBITORS IN DEVELOPMENT	467
TABLE 288 GLOBAL JAKAFI/RUXOLITINIB MARKET, THROUGH 2020 (\$ MILLIONS)	468
TABLE 289 GLOBAL MYELOFIBROSIS MARKET, THROUGH 2020 (\$ MILLIONS)	471
TABLE 290 GLOBAL POLYCYTHEMIA VERA MARKET, THROUGH 2020 (\$ MILLIONS)	472
TABLE 291 MAJOR BLOOD DISORDER DRUG PATENT EXPIRIES, 2009-2015	475
TABLE 292 KEY BLOOD DISORDER DRUGS: PATENT EXPIRY	476
TABLE 293 DRUGS LOSING PATENT PROTECTION BY 2015, GLOBAL SALES 2010 (\$ MILLIONS)	476
TABLE 294 BIOLOGIC DRUG PATENT EXPIRIES	477
TABLE 295 NEW DRUG APPROVALS FOR BLOOD DISORDERS, 2012	479
TABLE 296 NEW DRUG APPROVALS FOR HEMATOLOGICAL CANCERS, 2012	480

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS, BY SEGMENT, 2012-2020 (\$ MILLIONS)	9
FIGURE 1 ESTIMATED INCIDENCE OF BLOOD CANCERS, IN THE U.S., 2011 VS. 2016 (PER 100,000 POPULATION)	207
FIGURE 2 ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2016 (NO.)	208
FIGURE 3 ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)	209
FIGURE 4 ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S., 2010-2016 (NO.)	215
FIGURE 5 ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008 (NO.)	216
FIGURE 6 PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.)	218
FIGURE 7 ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE, 2012 (NO.)	220
FIGURE 8 ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO.)	222
FIGURE 9 ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)	235
FIGURE 10 ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000)	237
FIGURE 11 ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES IN EU-27 COUNTRIES, 2012 (ESTIMATED RATES PER 100,000 POPULATION)	239
FIGURE 12 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)	241
FIGURE 13 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2012 (NO.)	242
FIGURE 14 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE, 2011-2016 (NO.)	243
FIGURE 15 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2012 (NO.)	244
FIGURE 16 ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2011 (NO.)	245
FIGURE 17 ESTIMATED NUMBER OF DEATHS FROM HODGKIN'S LYMPHOMA IN THE U.K., 2012 (NO.)	255
FIGURE 18 ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER 100,000 POPULATION)	258
FIGURE 19 ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, 2008 (PER 100,000 POPULATION)	260
FIGURE 20 ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016 (NO.)	265
FIGURE 21 ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S., 2011-2016 (NO.)	265
FIGURE 22 GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, 2012-2020 (\$ MILLIONS)	284
FIGURE 23 GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET, 2012-2020 (\$ MILLIONS)	290
FIGURE 24 GLOBAL IVD PRODUCTS MARKET, 2012-2020 (\$ MILLIONS)	301
FIGURE 25 U.S. IVD MARKET, 2012-2020 (\$ MILLIONS)	302
FIGURE 26 GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, 2012-2020 (\$ MILLIONS)	303
FIGURE 27 GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, 2015-2020 (\$ MILLIONS)	304

FIGURE TITLE	PAGE NO.
FIGURE 28 GLOBAL MOLECULAR DIAGNOSTICS MARKET, 2015-2020 (\$ MILLIONS)	306
FIGURE 29 GLOBAL POINT-OF-CARE TESTING MARKET, 2015-2020 (\$ MILLIONS)	308
FIGURE 30 GLOBAL MARKET FOR POC TESTS, 2015-2020 (\$ MILLIONS)	309
FIGURE 31 GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, 2015-2020 (\$ MILLIONS)	311
FIGURE 32 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS, BY TYPE, 2012-2020 (\$ MILLIONS)	316
FIGURE 33 GLOBAL ANEMIA TREATMENT MARKET, 2012-2020 (\$ MILLIONS)	320
FIGURE 34 KEY ANEMIA DRUGS SALES, 2012 AND 2015 (\$ MILLIONS)	323
FIGURE 35 GLOBAL NEORECORMON MARKET, 2010-2015* (\$ MILLIONS)	325
FIGURE 36 GLOBAL ANTITHROMBOTIC DRUG MARKET, BY TYPE, 2012-2020 (\$ MILLIONS)	338
FIGURE 37 GLOBAL ANTICOAGULANT DRUG MARKET, 2012-2020 (\$ MILLIONS)	341
FIGURE 38 GLOBAL ANTIPLATELET DRUG MARKET, 2012-2020 (\$ MILLIONS)	344
FIGURE 39 GLOBAL NEUTROPENIA DRUG MARKET, 2012-2020 (\$ MILLIONS)	369
FIGURE 40 GLOBAL HEMOPHILIA THERAPEUTICS MARKET, 2012-2020 (\$ MILLIONS)	374
FIGURE 41 GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, BY TYPE, 2010 (\$ MILLIONS)	378
FIGURE 42 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)	394
FIGURE 43 U.S. CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	395
FIGURE 44 EUROPEAN CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	396
FIGURE 45 JAPANESE CYTOTHERAPEUTICS MARKET, 2012 AND 2017 (\$ MILLIONS)	397
FIGURE 46 GLOBAL LEUKEMIA MARKET, BY TYPE, 2012-2020 (\$ MILLIONS)	401
FIGURE 47 U.S. LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)	403
FIGURE 48 EUROPEAN LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)	403
FIGURE 49 JAPAN'S LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)	404
FIGURE 50 GLOBAL LEUKEMIA MARKET BY REGION, 2012-2020 (\$ MILLIONS)	405
FIGURE 51 GLOBAL CHRONIC MYELOGENOUS LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)	408
FIGURE 52 KEY CHRONIC MYELOGENOUS LEUKEMIA MARKET, BY DRUG, 2010-2015 (\$ MILLIONS)	410
FIGURE 53 GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, 2012-2020 (\$ MILLIONS)	420
FIGURE 54 GLOBAL ACUTE MYELOID LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)	426
FIGURE 55 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, 2012-2020 (\$ MILLIONS)	432
FIGURE 56 GLOBAL NON-HODGKIN LYMPHOMA DRUG MARKET, 2012-2020 (\$ MILLIONS)	448
FIGURE 57 GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET, 2012-2020 (\$ MILLIONS)	453
FIGURE 58 GLOBAL MULTIPLE MYELOMA TREATMENT MARKET, 2012-2020 (\$ MILLIONS)	457
FIGURE 59 GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET, 2012-2020 (\$ MILLIONS)	463
FIGURE 60 GLOBAL MYELOPROLIFERATIVE DISORDERS MARKET, 2012-2020 (\$ MILLIONS)	466
FIGURE 61 GLOBAL MYELOFIBROSIS MARKET, 2012-2020 (\$ MILLIONS)	471
FIGURE 62 GLOBAL POLYCYTHEMIA VERA MARKET, 2012-2020 (\$ MILLIONS)	473